HCC

A supplemental Biologics License Application for the combination of nivolumab and ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib has been accepted by the FDA and given Priority Review status. The supplemental Biologics License Applicationwas given a Prescription Drug User Fee Act goal date of March 10, 2020, according to a press release from Bristol-Myers Squibb.<br /> &nbsp;

Wasif M. Saif, MD, discusses available novel therapies for hepatocelluclar carcinoma.

In solid tumor oncology, an evolving treatment paradigm is getting more and more attention&mdash;and no, I&rsquo;m not referring to immunotherapy. In localized solid tumors, surgery is often a standard of care, with intent being toward cure.

Non-Hodgkin Lymphoma

The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br /> &nbsp;

Madappa Kundranda, MD, PhD, discusses the frontline therapeutic options for patients with newly diagnosed hepatocellular carcinoma who are not candidates for surgery or transplant.

Atezolizumab and bevacizumab demonstrated a statistically significant improvement in both progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma who have not received previous systemic therapy; this met both of the co-primary endpoints of the phase III IMbrave150 trial.

In an interview with&nbsp;Targeted Oncology&nbsp;at the ILCA conference, Rimola, radiologist, Radiology Department, Barcelona Clinic Liver Cancer Group, University of Barcelona, explained how assessment criteria may change patterns of progression and ultimately change outcomes in patients with advanced HCC treated with nivolumab.

In an interview with Targeted Oncology, Amit Singal, MD, MS,&nbsp;discussed issues with surveillance in patients with NASH, with or without cirrhosis. He also highlighted how combatting these issues can help improve the survival of patients with NASH-related HCC.

What is the ideal first-line therapy for nonresectable, non&ndash;transplantable eligible, liver-only hepatocellular carcinoma? In a debate at the 2019 Gastrointestinal Oncology Conference, Mark Yarchoan, MD, had the unenviable task of convincing the audience that systemic therapy was the way to go.

Ghassan K. Abou-Alfa, MD, discusses the current role for ramucirumab for the treatment of patients with hepatocellular carcinoma in the second-line setting.

In an interview with&nbsp;<em>Targeted Oncology</em>, LMichael S. Lee, MD, discussed the early data on the combination of atezolizumab and bevacizumab in patients with unresectable HCC. He also highlighted the importance of further validation, like the phase III IMbrave150 study, which is comparing the combination to the standard of care.

Refractory Hepatocellular Carcinoma

Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.